These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 32255344)
1. Advances in the Development of Phosphodiesterase-4 Inhibitors. Peng T; Qi B; He J; Ke H; Shi J J Med Chem; 2020 Oct; 63(19):10594-10617. PubMed ID: 32255344 [TBL] [Abstract][Full Text] [Related]
2. Advances in the development of phosphodiesterase-4 inhibitors. Li G; He D; Cai X; Guan W; Zhang Y; Wu JQ; Yao H Eur J Med Chem; 2023 Mar; 250():115195. PubMed ID: 36809706 [TBL] [Abstract][Full Text] [Related]
3. Advances in the development of phosphodiesterase 7 inhibitors. Huang JX; Zhu BL; Xu JP; Zhou ZZ Eur J Med Chem; 2023 Mar; 250():115194. PubMed ID: 36796299 [TBL] [Abstract][Full Text] [Related]
4. PDE4 inhibitors for disease therapy: advances and future perspective. Du B; Luo M; Ren C; Zhang J Future Med Chem; 2023 Jul; 15(13):1185-1207. PubMed ID: 37470147 [TBL] [Abstract][Full Text] [Related]
5. PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes. Jin J; Mazzacuva F; Crocetti L; Giovannoni MP; Cilibrizzi A Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511275 [TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions. Parikh N; Chakraborti AK Curr Med Chem; 2016; 23(2):129-41. PubMed ID: 26572614 [TBL] [Abstract][Full Text] [Related]
7. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803 [TBL] [Abstract][Full Text] [Related]
8. Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement. Wei X; Yu G; Shen H; Luo Y; Shang T; Shen R; Xi M; Sun H Bioorg Chem; 2023 Jan; 130():106278. PubMed ID: 36413930 [TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders. Wu C; Rajagopalan S Obes Rev; 2016 May; 17(5):429-41. PubMed ID: 26997580 [TBL] [Abstract][Full Text] [Related]
10. Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases. Carzaniga L; Amari G; Rizzi A; Capaldi C; De Fanti R; Ghidini E; Villetti G; Carnini C; Moretto N; Facchinetti F; Caruso P; Marchini G; Battipaglia L; Patacchini R; Cenacchi V; Volta R; Amadei F; Pappani A; Capacchi S; Bagnacani V; Delcanale M; Puccini P; Catinella S; Civelli M; Armani E J Med Chem; 2017 Dec; 60(24):10026-10046. PubMed ID: 29200281 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment. Zhang R; Li H; Zhang X; Li J; Su H; Lu Q; Dong G; Dou H; Fan C; Gu Z; Mu Q; Tang W; Xu Y; Liu H Eur J Med Chem; 2021 Feb; 211():113004. PubMed ID: 33218684 [TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents. Barberot C; Moniot A; Allart-Simon I; Malleret L; Yegorova T; Laronze-Cochard M; Bentaher A; Médebielle M; Bouillon JP; Hénon E; Sapi J; Velard F; Gérard S Eur J Med Chem; 2018 Feb; 146():139-146. PubMed ID: 29407945 [TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 4 inhibitors in diabetic nephropathy. Ookawara M; Nio Y Cell Signal; 2022 Feb; 90():110185. PubMed ID: 34785349 [TBL] [Abstract][Full Text] [Related]
15. Discovery of oxazole-based PDE4 inhibitors with picomolar potency. Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864 [TBL] [Abstract][Full Text] [Related]
16. Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4. Cai YH; Guo Y; Li Z; Wu D; Li X; Zhang H; Yang J; Lu H; Sun Z; Luo HB; Yin S; Wu Y Eur J Med Chem; 2016 May; 114():134-40. PubMed ID: 26978121 [TBL] [Abstract][Full Text] [Related]
17. New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies. Guariento S; Bruno O; Fossa P; Cichero E Mol Divers; 2016 Feb; 20(1):77-92. PubMed ID: 26290462 [TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of 4,5,6,7-tetrahydro-1H-1,2-diazepin-7-one derivatives as a new series of Phosphodiesterase 4 (PDE4) inhibitors. Guariento S; Karawajczyk A; Bull JA; Marchini G; Bielska M; Iwanowa X; Bruno O; Fossa P; Giordanetto F Bioorg Med Chem Lett; 2017 Jan; 27(1):24-29. PubMed ID: 27890378 [TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling and virtual screening for the discovery of new type 4 cAMP phosphodiesterase (PDE4) inhibitors. Niu M; Dong F; Tang S; Fida G; Qin J; Qiu J; Liu K; Gao W; Gu Y PLoS One; 2013; 8(12):e82360. PubMed ID: 24340020 [TBL] [Abstract][Full Text] [Related]
20. TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model. Demizu S; Asaka N; Kawahara H; Sasaki E Eur J Pharmacol; 2019 Apr; 849():22-29. PubMed ID: 30716315 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]